Meeting
2015 Genitourinary Cancers Symposium
Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).
Authors
Alice Clement-Zhao
Department of Medical Oncology, Hôpital Européen Georges Pompidou, Paris, France
Alice Clement-Zhao , Marie Auvray , Benjamin Verret , Yann Alexandre Vano , Antoine Angelergues , Stephane Oudard
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Testicular, and Urethral Cancers, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 284)
DOI
10.1200/jco.2015.33.7_suppl.284
Abstract #
284
Poster Bd #
E2
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Efficacy and safety in older patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving cabazitaxel (CBZ) versus abiraterone (ABI) or enzalutamide (ENZ) in the CARD study.
First Author: Cora N. Sternberg
Poster
2018 Genitourinary Cancers Symposium
Safety and efficacy of abiraterone acetate (AA) in patients aged 75 or more with metastatic castration-resistant prostate cancer (mCRPC) in both pre-chemotherapy or post-chemotherapy settings: Real-life experience from thirteen Italian centers.
First Author: Zuzana Sirotova
Poster
2017 ASCO Annual Meeting
Efficacy of cabazitaxel (CABA) rechallenge in heavily-treated patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Constance Thibault
First Author: Matthew Raymond Smith